185 related articles for article (PubMed ID: 12879737)
1. Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
Fazeny-Dörner B; Gyries A; Rössler K; Ungersböck K; Czech T; Budinsky A; Killer M; Dieckmann K; Piribauer M; Baumgartner G; Prayer D; Veitl M; Muhm M; Marosi C
Wien Klin Wochenschr; 2003 Jun; 115(11):389-97. PubMed ID: 12879737
[TBL] [Abstract][Full Text] [Related]
2. Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Balducci M; Chiesa S; Diletto B; D'Agostino GR; Mangiola A; Manfrida S; Mantini G; Albanese A; Fiorentino A; Frascino V; De Bari B; Micciche' F; De Rose F; Morganti AG; Anile C; Valentini V
Neuro Oncol; 2012 Jan; 14(1):79-86. PubMed ID: 21993440
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Brandes AA; Rigon A; Zampieri P; Ermani M; Carollo C; Altavilla G; Turazzi S; Chierichetti F; Florentino MV
Cancer; 1998 Jan; 82(2):355-61. PubMed ID: 9445194
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Fazeny-Dörner B; Veitl M; Wenzel C; Piribauer M; Rössler K; Dieckmann K; Ungersböck K; Marosi C
Anticancer Drugs; 2003 Jul; 14(6):437-42. PubMed ID: 12853885
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
10. Preradiation chemotherapy with VM-26 and CCNU in patients with glioblastoma multiforme.
Mañé JM; Fernández R; Muñoz A; Rubio I; Ferreiro J; López-Argumedo G; Barceló R; López-Vivanco G
Tumori; 2004; 90(6):562-6. PubMed ID: 15762357
[TBL] [Abstract][Full Text] [Related]
11. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
[TBL] [Abstract][Full Text] [Related]
12. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL
Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
[No Abstract] [Full Text] [Related]
14. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
Brandes AA; Rigon A; Zampieri P; Scelzi E; Amistà P; Berti F; Rotilio A; Gardiman M; Fiorentino MV
J Neurooncol; 1996 Dec; 30(3):247-55. PubMed ID: 8943100
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
17. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
[TBL] [Abstract][Full Text] [Related]
18. Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B; Wenzel C; Veitl M; Piribauer M; Rössler K; Dieckmann K; Ungersböck K; Marosi C
Anticancer Drugs; 2003 Apr; 14(4):305-12. PubMed ID: 12679735
[TBL] [Abstract][Full Text] [Related]
19. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]